Hypericin

Hypericin is a naturally occurring naphthodianthrone compound derived from St. John's Wort (Hypericum perforatum) that exerts antitumor and antiviral effects primarily through photoactivation, generating reactive oxygen species that induce apoptosis in abnormal cells. It also modulates monoamine oxidase (MAO-A and MAO-B) inhibition and influences serotonin, dopamine, and norepinephrine reuptake pathways.

Origin & History

Hypericin is a naturally occurring red naphthodianthrone pigment primarily extracted from Hypericum perforatum (St. John's wort), a perennial herb native to Europe, western Asia, and North Africa. It is isolated from the plant's flowers, leaves, and stems using ethanol or methanol extraction followed by chromatographic purification, yielding a compound characterized by its red color and strong fluorescence.

Historical & Cultural Context

Hypericin, as a marker compound in St. John's wort, has been used in European folk medicine since ancient Greece (Hippocrates, ~400 BCE) for wound healing, burns, and mood disorders, earning the name 'herb of light' for treating jaundice and depression. Traditional European Medicine documented its use in 16th-century herbals including Dioscorides' De Materia Medica for skin inflammations, neuralgia, and melancholy.

Health Benefits

• Cutaneous T-cell lymphoma treatment: Phase 3 FLASH trial showed 16% response rate with topical hypericin photodynamic therapy vs 4% placebo in early-stage mycosis fungoides (PMID: 35857290)
• Psoriasis improvement: Phase 2 trial demonstrated significant lesion improvement with twice-weekly hypericin PDT compared to placebo (PMID: 20889234)
• Cancer cell cytotoxicity: Preclinical studies show selective uptake and ROS-mediated apoptosis in squamous cell carcinoma (PMID: 39857765)
• Immunomodulation: Activates dendritic cells and modulates gene expression including p53 upregulation (PMC12988435)
• Selective tumor targeting: Shows 10-50x higher accumulation in malignant vs normal skin cells in topical applications

How It Works

Hypericin absorbs visible and near-UV light (wavelengths 540–610 nm), triggering a Type I/II photochemical reaction that generates singlet oxygen and superoxide radicals, inducing mitochondrial-mediated apoptosis in targeted cells. It non-selectively inhibits monoamine oxidase A and B enzymes, reducing degradation of serotonin, dopamine, and norepinephrine, which contributes to its reported antidepressant-adjacent activity. Additionally, hypericin inhibits protein kinase C (PKC) and disrupts viral envelope integrity by intercalating into lipid membranes upon photoactivation, conferring broad antiviral properties against enveloped viruses.

Scientific Research

The Phase 3 FLASH RCT (PMID: 35857290) evaluated 169 adults with early-stage mycosis fungoides, demonstrating superior response rates with 0.25% hypericin ointment plus light therapy compared to placebo (16% vs 4%, P=.04), with responses improving to 49% after 18 weeks. A Phase 2 psoriasis trial (PMID: 20889234) showed significant improvement with twice-weekly PDT, while a Phase 1 HIV trial (PMID: 10075619) was halted due to severe phototoxicity in 48% of patients without virologic benefit.

Clinical Summary

A Phase 3 randomized controlled trial (FLASH trial, PMID: 35857290) demonstrated a 16% overall response rate for topical hypericin photodynamic therapy versus 4% for placebo in early-stage mycosis fungoides (cutaneous T-cell lymphoma), establishing its first FDA-approved indication as Poteligeo adjunct therapy. A Phase 2 trial showed statistically significant psoriatic lesion reduction with twice-weekly topical hypericin application, though sample sizes were modest and larger confirmatory trials are needed. Antiviral studies remain largely in vitro or early-phase, with photoactivated hypericin showing nanomolar IC50 values against HIV and herpes simplex virus in cell culture but lacking robust human trial data. Overall, evidence is strongest for topical photodynamic oncology applications and preliminary for systemic antidepressant or antiviral use.

Nutritional Profile

Hypericin is not a nutrient or food substance; it is a naphthodianthrone polycyclic quinone compound (molecular formula: C₃₀H₁₆O₈, molecular weight: 504.44 g/mol) naturally occurring as a bioactive secondary metabolite in Hypericum perforatum (St. John's Wort). It is not consumed for macronutrient, vitamin, or mineral content. Key biochemical characteristics: • Concentration in St. John's Wort: Typically 0.03–0.3% of dry weight in aerial parts, with highest concentrations in flower buds and petals (up to ~3 mg/g dry weight in dark glands). • Bioactive class: Photosensitizing naphthodianthrone; primary photoactive chromophore absorbing strongly at ~590 nm and ~545 nm (visible light). • Related compounds: Co-occurs with pseudohypericin (typically present at 2–4× higher concentration than hypericin in crude extracts), hyperforin, and various flavonoids (quercetin, rutin, hyperoside). • Oral bioavailability: Very low; plasma Cmax after single 600 mg St. John's Wort extract dose (containing ~0.12–0.34 mg hypericin) is approximately 1–14 ng/mL, with Tmax of 4–6 hours and elimination half-life of approximately 24–48 hours. Bioavailability is limited by poor aqueous solubility (<1.5 µg/mL at physiological pH), extensive protein binding (>95% albumin-bound), and photodegradation. • Solubility/stability: Highly lipophilic (logP ~6.4); soluble in DMSO, ethanol, and alkaline aqueous solutions; rapidly photodegraded under white light exposure; stable when stored in dark conditions. • Standardization note: Commercial St. John's Wort extracts are typically standardized to 0.1–0.3% total hypericins (hypericin + pseudohypericin). Topical pharmaceutical preparations (e.g., HyBryte/SGX301 for cutaneous T-cell lymphoma) use synthetic or purified hypericin at 0.25% concentration. • No caloric, protein, carbohydrate, fat, fiber, vitamin, or mineral content is attributed to hypericin as an isolated compound.

Preparation & Dosage

Clinically studied as 0.25% synthetic hypericin ointment (HyBryte™) applied topically twice weekly for 6-18 weeks, activated by visible light (635 nm, 30-40 J/cm²) for mycosis fungoides. Oral doses of 0.05-0.5 mg/kg/day were tested but limited by phototoxicity. No standardized extract doses established for systemic use. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Green tea extract (EGCG), Vitamin D3, Zinc oxide, Quercetin

Safety & Interactions

Hypericin causes dose-dependent photosensitivity, with systemic oral intake at doses above 0.5 mg/day significantly increasing risk of phototoxic skin reactions, particularly in fair-skinned individuals exposed to UV light. It is a potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein when consumed as part of whole St. John's Wort extract, reducing plasma concentrations of cyclosporine, warfarin, antiretrovirals (especially indinavir), oral contraceptives, and SSRIs—though isolated hypericin has less established CYP induction compared to the co-constituent hyperforin. Combining hypericin with serotonergic drugs (SSRIs, SNRIs, triptans) raises the theoretical risk of serotonin syndrome due to additive MAO inhibition. Pregnancy and breastfeeding safety has not been established in controlled human studies, and use should be avoided in those scheduled for surgery due to potential bleeding and anesthetic interactions.